• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向DNA双链断裂修复途径的化疗化合物:益处、弊端与前景。

Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising.

作者信息

Jekimovs Christian, Bolderson Emma, Suraweera Amila, Adams Mark, O'Byrne Kenneth J, Richard Derek J

机构信息

Cancer and Ageing Research Program, Institute of Health and Biomedical Innovation, Queensland University of Technology , Brisbane, QLD , Australia.

出版信息

Front Oncol. 2014 Apr 22;4:86. doi: 10.3389/fonc.2014.00086. eCollection 2014.

DOI:10.3389/fonc.2014.00086
PMID:24795863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4001069/
Abstract

The repair of DNA double-strand breaks (DSBs) is a critical cellular mechanism that exists to ensure genomic stability. DNA DSBs are the most deleterious type of insult to a cell's genetic material and can lead to genomic instability, apoptosis, or senescence. Incorrectly repaired DNA DSBs have the potential to produce chromosomal translocations and genomic instability, potentially leading to cancer. The prevalence of DNA DSBs in cancer due to unregulated growth and errors in repair opens up a potential therapeutic window in the treatment of cancers. The cellular response to DNA DSBs is comprised of two pathways to ensure DNA breaks are repaired: homologous recombination and non-homologous end joining. Identifying chemotherapeutic compounds targeting proteins involved in these DNA repair pathways has shown promise as a cancer therapy for patients, either as a monotherapy or in combination with genotoxic drugs. From the beginning, there have been a number of chemotherapeutic compounds that have yielded successful responses in the clinic, a number that have failed (CGK-733 and iniparib), and a number of promising targets for future studies identified. This review looks in detail at how the cell responds to these DNA DSBs and investigates the chemotherapeutic avenues that have been and are currently being explored to target this repair process.

摘要

DNA双链断裂(DSB)的修复是一种关键的细胞机制,其存在的目的是确保基因组稳定性。DNA DSB是对细胞遗传物质最具危害性的损伤类型,可导致基因组不稳定、细胞凋亡或衰老。修复错误的DNA DSB有可能产生染色体易位和基因组不稳定,进而可能导致癌症。由于生长失控和修复错误,DNA DSB在癌症中普遍存在,这为癌症治疗开辟了一个潜在的治疗窗口。细胞对DNA DSB的反应由两条途径组成,以确保DNA断裂得到修复:同源重组和非同源末端连接。鉴定针对这些DNA修复途径中相关蛋白的化疗化合物,已显示出有望成为一种癌症治疗方法,无论是作为单一疗法还是与基因毒性药物联合使用。从一开始,就有许多化疗化合物在临床上取得了成功的疗效,有一些失败了(如CGK - 733和依尼帕利),同时也确定了一些未来研究中很有前景的靶点。这篇综述详细探讨了细胞如何对这些DNA DSB做出反应,并研究了过去和目前正在探索的针对这一修复过程的化疗途径。

相似文献

1
Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising.靶向DNA双链断裂修复途径的化疗化合物:益处、弊端与前景。
Front Oncol. 2014 Apr 22;4:86. doi: 10.3389/fonc.2014.00086. eCollection 2014.
2
Kinesin Kif2C in regulation of DNA double strand break dynamics and repair.驱动蛋白 Kif2C 在调控 DNA 双链断裂动态变化和修复中的作用。
Elife. 2020 Jan 17;9:e53402. doi: 10.7554/eLife.53402.
3
Pathways and assays for DNA double-strand break repair by homologous recombination.同源重组修复 DNA 双链断裂的途径和分析。
Acta Biochim Biophys Sin (Shanghai). 2019 Sep 6;51(9):879-889. doi: 10.1093/abbs/gmz076.
4
One end to rule them all: Non-homologous end-joining and homologous recombination at DNA double-strand breaks.一以贯之:DNA 双链断裂处的非同源末端连接和同源重组。
Br J Radiol. 2020 Nov 1;93(1115):20191054. doi: 10.1259/bjr.20191054. Epub 2020 Feb 28.
5
Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks.分析着丝粒断裂修复检测到同源重组向非同源末端连接的转换,这种转换随着 DNA 双链断裂负荷的增加而增加。
Mutat Res Genet Toxicol Environ Mutagen. 2021 Jul;867:503372. doi: 10.1016/j.mrgentox.2021.503372. Epub 2021 Jun 12.
6
The Determinant of DNA Repair Pathway Choices in Ionising Radiation-Induced DNA Double-Strand Breaks.电离辐射诱导的 DNA 双链断裂中 DNA 修复途径选择的决定因素。
Biomed Res Int. 2020 Aug 25;2020:4834965. doi: 10.1155/2020/4834965. eCollection 2020.
7
DNA double-strand break repair by homologous recombination.通过同源重组进行DNA双链断裂修复。
Biol Chem. 2002 Jun;383(6):873-92. doi: 10.1515/BC.2002.095.
8
Double-strand break repair-adox: Restoration of suppressed double-strand break repair during mitosis induces genomic instability.双链断裂修复-adoX:有丝分裂期间受抑制的双链断裂修复的恢复导致基因组不稳定性。
Cancer Sci. 2014 Dec;105(12):1519-25. doi: 10.1111/cas.12551. Epub 2014 Nov 5.
9
The complexity of DNA double strand breaks is a critical factor enhancing end-resection.DNA 双链断裂的复杂性是增强末端切除的关键因素。
DNA Repair (Amst). 2013 Nov;12(11):936-46. doi: 10.1016/j.dnarep.2013.08.009. Epub 2013 Sep 13.
10
How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability.癌细胞如何劫持DNA双链断裂修复途径以获得基因组不稳定。
Biochem J. 2015 Oct 1;471(1):1-11. doi: 10.1042/BJ20150582.

引用本文的文献

1
Epigenetic drugs in cancer therapy.用于癌症治疗的表观遗传药物。
Cancer Metastasis Rev. 2025 Feb 26;44(1):37. doi: 10.1007/s10555-025-10253-7.
2
Cocaine-Induced DNA-Dependent Protein Kinase Relieves RNAP II Pausing by Promoting TRIM28 Phosphorylation and RNAP II Hyperphosphorylation to Enhance HIV Transcription.可卡因诱导的DNA依赖性蛋白激酶通过促进TRIM28磷酸化和RNA聚合酶II的过度磷酸化来缓解RNA聚合酶II的暂停,从而增强HIV转录。
Cells. 2024 Nov 23;13(23):1950. doi: 10.3390/cells13231950.
3
Cocaine-induced DNA-PK relieves RNAP II pausing by promoting TRIM28 phosphorylation.

本文引用的文献

1
Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.靶向非同源末端连接修复途径的组分可使 KRAS 突变型白血病细胞对化疗敏感。
Blood. 2014 Apr 10;123(15):2355-66. doi: 10.1182/blood-2013-01-477620. Epub 2014 Feb 6.
2
Resveratrol and cancer: focus on in vivo evidence.白藜芦醇与癌症:关注体内证据。
Endocr Relat Cancer. 2014 May 6;21(3):R209-25. doi: 10.1530/ERC-13-0171. Print 2014 Jun.
3
Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
可卡因诱导的DNA依赖性蛋白激酶通过促进TRIM28磷酸化来缓解RNA聚合酶II的暂停。
bioRxiv. 2024 Aug 19:2024.08.19.608673. doi: 10.1101/2024.08.19.608673.
4
Identification and Validation of New DNA-PKcs Inhibitors through High-Throughput Virtual Screening and Experimental Verification.通过高通量虚拟筛选和实验验证鉴定和验证新的 DNA-PKcs 抑制剂。
Int J Mol Sci. 2024 Jul 22;25(14):7982. doi: 10.3390/ijms25147982.
5
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.在转移性尿路上皮癌中进行 APOBEC 诱变的全基因组图谱分析,确定了驱动热点突变和一个新的突变特征。
Cell Genom. 2024 Apr 10;4(4):100528. doi: 10.1016/j.xgen.2024.100528. Epub 2024 Mar 28.
6
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.在晚期实体瘤患者中开展的 peposertib 联合avelumab 或不联合姑息性放疗的 I 期研究。
ESMO Open. 2024 Feb;9(2):102217. doi: 10.1016/j.esmoop.2023.102217. Epub 2024 Feb 5.
7
6-Methoxydihydrosanguinarine exhibits cytotoxicity and sensitizes TRAIL-induced apoptosis of hepatocellular carcinoma cells through ROS-mediated upregulation of DR5.6-甲氧基二氢血根碱通过 ROS 介导致 DR5 上调表现出细胞毒性,并增强 TRAIL 诱导的肝癌细胞凋亡。
Med Oncol. 2023 Aug 11;40(9):266. doi: 10.1007/s12032-023-02129-z.
8
Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology.利用细胞条形码技术鉴定化疗诱导的耐药性的旁系敏感性和进化格局。
Front Pharmacol. 2023 Jul 11;14:1178489. doi: 10.3389/fphar.2023.1178489. eCollection 2023.
9
Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair.靶向DNA双链断裂修复的非PIKKs小分子抑制剂开发的最新进展
Front Oncol. 2022 Apr 6;12:850883. doi: 10.3389/fonc.2022.850883. eCollection 2022.
10
A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress.一种具有临床意义的杂合 ATR 突变使结直肠癌细胞对复制应激敏感。
Sci Rep. 2022 Mar 31;12(1):5422. doi: 10.1038/s41598-022-09308-4.
鉴定双重 DNA-PK/MDR1 抑制剂以增强细胞毒药物活性。
Biochem Pharmacol. 2014 Mar 1;88(1):58-65. doi: 10.1016/j.bcp.2014.01.001. Epub 2014 Jan 10.
4
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.Chk1 抑制剂 MK-8776 增敏人癌细胞对吉西他滨的作用:细胞周期干扰及体内外给药方案的影响。
BMC Cancer. 2013 Dec 21;13:604. doi: 10.1186/1471-2407-13-604.
5
Double-strand break repair: 53BP1 comes into focus.双链断裂修复:53BP1 成为焦点。
Nat Rev Mol Cell Biol. 2014 Jan;15(1):7-18. doi: 10.1038/nrm3719. Epub 2013 Dec 11.
6
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.LY2603618的特性及临床前开发:一种选择性强效Chk1抑制剂
Invest New Drugs. 2014 Apr;32(2):213-26. doi: 10.1007/s10637-013-0036-7. Epub 2013 Oct 10.
7
DNA double strand break repair via non-homologous end-joining.通过非同源末端连接进行DNA双链断裂修复。
Transl Cancer Res. 2013 Jun;2(3):130-143. doi: 10.3978/j.issn.2218-676X.2013.04.02.
8
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.AZD7762 单药及联合吉西他滨治疗日本晚期实体瘤患者的 I 期剂量递增研究。
Cancer Chemother Pharmacol. 2013 Sep;72(3):619-27. doi: 10.1007/s00280-013-2234-6. Epub 2013 Jul 28.
9
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.BMN 673,一种新型高效的 PARP1/2 抑制剂,用于治疗具有 DNA 修复缺陷的人类癌症。
Clin Cancer Res. 2013 Sep 15;19(18):5003-15. doi: 10.1158/1078-0432.CCR-13-1391. Epub 2013 Jul 23.
10
A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.基于合成致死策略治疗携带染色质重塑因子 BRG1 遗传缺陷的癌症。
Cancer Res. 2013 Sep 1;73(17):5508-18. doi: 10.1158/0008-5472.CAN-12-4593. Epub 2013 Jul 19.